|
|
News Breaks | | | | January 23, 2013 | | 16:16 EDT |  | NBIX | Neurocrine Biosciences announces VMAT2 inhibitor granted two more patents
Neurocrine Biosciences announced that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, or VMAT2. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. The United States Patent and Trademark Office recently granted a second patent. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027. | |
|
News For NBIX From The Last 14 Days Check below for free stories on NBIX the last two weeks. |
|
|
| June 18, 2013 | | 16:09 EDT |  | NBIX | Neurocrine Biosciences initiated with an Outperform at Oppenheimer
Target $16. | | | June 17, 2013 | | 11:50 EDT |  | NBIX | Neurocrine Biosciences management to meet with Oppenheimer
Meeting to be held in Europe on June 21 hosted by Oppenheimer. | |
|
|
|
|
|
|
